11 hours ago
Asian Stocks Estimated Below Intrinsic Value In June 2025
Amidst escalating geopolitical tensions in the Middle East and ongoing trade discussions, Asian markets have been navigating a complex landscape, with mixed performances across major indices. As investors seek opportunities in this environment, identifying stocks that are potentially undervalued relative to their intrinsic value can be a strategic approach to capitalizing on market fluctuations.
Name
Current Price
Fair Value (Est)
Discount (Est)
Taiwan Union Technology (TPEX:6274)
NT$216.50
NT$424.21
49%
StemCell Institute (TSE:7096)
¥1070.00
¥2118.09
49.5%
Shenzhen KSTAR Science and Technology (SZSE:002518)
CN¥21.98
CN¥43.55
49.5%
PixArt Imaging (TPEX:3227)
NT$219.50
NT$436.51
49.7%
Peijia Medical (SEHK:9996)
HK$6.43
HK$12.71
49.4%
Livero (TSE:9245)
¥1719.00
¥3376.98
49.1%
Good Will Instrument (TWSE:2423)
NT$43.90
NT$87.32
49.7%
Food & Life Companies (TSE:3563)
¥6579.00
¥12942.09
49.2%
Dive (TSE:151A)
¥917.00
¥1832.47
50%
cottaLTD (TSE:3359)
¥442.00
¥866.08
49%
Click here to see the full list of 292 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
Here we highlight a subset of our preferred stocks from the screener.
Overview: S&D Co., Ltd, with a market cap of ₩397.75 billion, develops and sells health functional food in South Korea.
Operations: Revenue Segments (in millions of ₩):
Estimated Discount To Fair Value: 23.1%
S&D Co., Ltd is trading at ₩137,500, which is 23.1% below its estimated fair value of ₩178,875.67, indicating it may be undervalued based on cash flows. The company's earnings are forecast to grow significantly at 23.4% annually, outpacing the Korean market's average growth rate of 21%. Revenue growth is also expected to exceed market averages at 20.9% per year. However, recent share price volatility could pose risks for investors seeking stability.
The analysis detailed in our S&D growth report hints at robust future financial performance.
Click to explore a detailed breakdown of our findings in S&D's balance sheet health report.
Overview: DPC Dash Ltd, along with its subsidiaries, runs a chain of fast-food restaurants in the People's Republic of China and has a market cap of HK$12.92 billion.
Operations: The company generates revenue primarily from its chain of fast-food restaurants in the People's Republic of China, totaling CN¥4.31 billion.
Estimated Discount To Fair Value: 17.9%
DPC Dash Ltd, trading at HK$98.7, is priced 17.9% below its fair value estimate of HK$120.2, reflecting potential undervaluation based on cash flows. The company recently turned profitable with net income of CNY 55.2 million and expects earnings to grow significantly at 51.3% annually, surpassing the Hong Kong market's growth rate of 10.6%. However, significant insider selling over the past quarter could be a concern for investors evaluating stability and confidence in future performance.
Our growth report here indicates DPC Dash may be poised for an improving outlook.
Click here and access our complete balance sheet health report to understand the dynamics of DPC Dash.
Overview: Peijia Medical Limited, with a market cap of HK$4.28 billion, focuses on the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China.
Operations: Peijia Medical generates revenue from its Neurointerventional Business, which accounts for CN¥355.55 million, and its Transcatheter Valve Therapeutic Business, contributing CN¥259.94 million.
Estimated Discount To Fair Value: 49.4%
Peijia Medical, trading at HK$6.43, is significantly undervalued based on cash flows with a fair value estimate of HK$12.71. Despite reporting a net loss of CNY 226.58 million in 2024, the company is expected to become profitable within three years and outpace market growth with projected revenue increases of 27.9% annually. Recent advancements include regulatory acceptance for innovative medical devices and successful clinical trials, potentially enhancing future revenue streams and investor confidence.
Upon reviewing our latest growth report, Peijia Medical's projected financial performance appears quite optimistic.
Take a closer look at Peijia Medical's balance sheet health here in our report.
Delve into our full catalog of 292 Undervalued Asian Stocks Based On Cash Flows here.
Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A260970 SEHK:1405 and SEHK:9996.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
